Drug Trial Radar · NCT07234942
A Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of RO7812653 in Participants With Early Symptomatic Alzheimer's Disease (eAD)
Last checked: Nov 20, 2026Latest source record: Sep 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
6
Actual
Start
Jan 27, 2026
Primary completion
Mar 31, 2027
Study completion Mar 31, 2027
Sponsor
- Lead sponsor
- Hoffmann-La RocheRoche (Genentech) (RHHBY)
- Sponsor type
- Industry
- First posted
- Nov 19, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 50 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study aims to evaluate the safety, tolerability, immunogenicity, pharmacokinetics, and pharmacodynamics following administration of RO7812653 in participants with eAD.
Conditions
- Alzheimer's Disease
Interventions
RO7812653Drug
Participants will receive RO7812653 as per the schedule in the protocol
PlaceboDrug
Participants will receive placebo as per the schedule in the protocol
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants with Adverse EventsTime frame: Up to approximately 40 weeks
- Change From Baseline in Columbia-Suicide Severity Rating Scale (C-SSRS) ScoresTime frame: Up to approximately 40 weeks
Locations
12 sites in 5 countries. Site status is shown where the registry gives one.
Toronto Western Hospital
Toronto, Ontario, Canada
Montreal Neurological Institute Clinical Research Unit
Montreal, Quebec, Canada
Brain Research Center Amsterdam
Amsterdam, North Holland, Netherlands
Hospital de la Santa Creu i Sant Pau
Barcelona, Spain
Hospital Universitario Reina Sofia
Córdoba, Spain
Hospital General de Catalunya
Sant Cugat del Vallès, Barcelona, Spain
Sahlgrenska Universitetssjukhuset, Mlndal Sjukhus
Mlndal, Sweden
Karolinska Universitetssjukhuset
Solna, Sweden
National Hospital For Neurology and Neurosurgery
London, United Kingdom
Institute of Psychiatry, Psychology and Neuroscience;Department of Old Age Psychiatry
London, Greater London, United Kingdom
Southampton General Hospital
Southampton, Hampshire, United Kingdom
Queen Elizabeth Hospital
Glasgow, Strathclyde, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.